Ages2Come
Menu
View all results →
Categories
⚡ Breaking
Australia posts second-quarter growth of 2.1%, beating expectations Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says Australia posts second-quarter growth of 2.1%, beating expectations Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says
Finance / General

Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess

Source: bloombergMarkets July 1, 2026 · 00:54
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.
Read original article ← Back to General

The original article opens on the publisher's website.

More from General

View topic →
Countries mentioned
Switzerland